Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.

Abstract

BACKGROUND:

It is crucial to identify risk factors for life prognosis after hepatitis C virus (HCV) eradication among patients with or without a high risk of liver cancer or complications.

METHODS:

This is a prospective, multicenter and observational study using the database of 1031 patients after HCV eradication by direct-acting antiviral agents (DAAs) to evaluate the development of hepatocellular carcinoma (HCC) and patients' survival after a sustained virological response (SVR). The Cox proportional hazards regression model was used to estimate hazard ratios associated with HCC development and survival.

RESULTS:

AFP at SVR was significantly associated with HCC recurrence in the adjusted model. Liver fibrosis, Mac-2 binding protein glycosylation isomer (M2BPGi) at SVR and smoking status before treatment were positively associated with the development of HCC and M2BPGi was positively associated with HCC recurrence, although not reaching statistical significance. Among patients without a history of HCC, M2BPGi and estimated glomerular filtration rate (eGFR) at SVR were significantly associated with death after viral eradication [M2BPGi (HR 4.07, 95% CI 1.22, 13.57), eGFR (HR 0.97, 95% CI 0.94, 0.99)]. Strikingly, of 16 patients who died, among participants without a history of HCC, only two died of liver cancer associated with HCV, whereas 11 died of non-HCV- related cancer or cardiovascular diseases.

CONCLUSION:

M2BPGi at SVR is a potential predictor for patients' survival and a candidate biomarker for detecting individuals who are at greater risk of death due to cancer-related and unrelated to HCV, as well as cardiovascular diseases, after viral eradication.

• Authors: Mina Nakagawa, Nobutoshi Nawa, Eiko Takeichi, Taro Shimizu, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Takeo Fujiwara, Mamoru Watanabe, Yujiro Tanaka, Yasuhiro Asahina, Ochanomizu Liver Conference Study Group
• Journal: Journal of gastroenterology (J Gastroenterol) Vol. 55 Issue 10 Pg. 990-999 (Oct 2020) ISSN: 1435-5922 [Electronic] Japan
• PMID: 32770465 (Publication Type: Journal Article, Multicenter Study, Observational Study)

Chemical References

• Antigens, Neoplasm
• Antiviral Agents
• Biomarkers, Tumor
• LGALS3BP protein, human

Topics

• Aged
• Aged, 80 and over
• Antigens, Neoplasm (metabolism)
• Antiviral Agents (administration & dosage)
• Biomarkers, Tumor (metabolism)
• Carcinoma, Hepatocellular (epidemiology, virology)
• Female
• Hepatitis C, Chronic (complications, drug therapy)
• Humans
• Liver Neoplasms (epidemiology, virology)
• Male
• Middle Aged
• Prognosis
• Prospective Studies
• Risk Factors
• Survival Rate
• Sustained Virologic Response